1,500+
The conference welcomed over 1,500 oncology leaders from 48 states, Puerto Rico and D.C.
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportDesigned to be the premier annual event for community oncology, the conference brought together a diverse audience of physicians, clinicians, administrators, industry leaders and biopharma representatives.
Read Time
2 minutes
Over 1,500 stakeholders in community oncology gathered November 2–5, 2025 at the inaugural 51Âþ»appAccelerate conference to share ideas and solutions to navigate the challenges they confront in today’s dynamic healthcare landscape.
Thought-provoking sessions led by renowned experts shed light on the trends and opportunities facing community oncology, such as rising costs, the complexity of novel therapies and precision medicine, reimbursement hurdles, artificial intelligence, leadership and the evolving regulatory landscape.
Attendees acquired not only deeper knowledge on these critical issues, but actionable insights and solutions to innovate while elevating patient care and strengthening practice viability.
“Successfully managing the complexity of modern cancer care is extremely difficult in today’s environment,” said Jason Hammonds, President, Oncology & Multispecialty, McKesson. “For the past 20 years, 51Âþ»apphas heavily invested in community oncology, and Accelerate provides practices the deep insights, tools and partnerships they need to succeed. Together, we are redefining cancer care to ensure community oncology is not just surviving, it’s thriving.”
The conference brought together leaders who are driving innovation, improving outcomes and shaping the future of community cancer care.
1,500+
The conference welcomed over 1,500 oncology leaders from 48 states, Puerto Rico and D.C.
59
Attendees benefited from 59 educational sessions.
100+
More than 100 inspiring speakers took the stage.
70
Participants explored 70 innovative exhibits.
More than just another industry event, Accelerate provided a launchpad for novel resources, idea sharing and connections to improve practice operations and cancer care in local communities.
The event featured a number of sessions highlighting the opportunity for collaboration with community oncology providers, biopharma leaders and key stakeholders, including in the Innovation Theater and Broadcast Center. These presentations showcased technologies, treatments and solutions that are transforming cancer care.
Biopharma exhibitors had the opportunity to highlight their latest advancements while facilitating insightful discussions with providers, clinicians and pharmacists around drug development, data sharing and clinical trials.
“Oncology is at the heart of our strategy because we believe, together with our partners, we can advance community oncology, bring great healthcare closer to where patients live and truly impact their lives,” said Brian Tyler, CEO, McKesson. “It’s a privilege to stand alongside providers and witness the incredible advancements they make every day. We are committed to supporting community oncologists to make their lives easier, amplify their impact on patient care and help win the fight against cancer.”
Bringing together 1,500 oncology leaders at Accelerate enabled a tremendous opportunity for problem-solving, networking and productive conversations.
The attendees, each with their own unique perspectives and skills, learned from one another, generated fresh ideas and formed connections that will be mutually beneficial.
51Âþ»appAccelerate is poised to become the essential annual event for community oncology, setting the stage for trailblazers and visionaries to come together and shape the future of cancer care.
Next year’s gathering is positioned to deliver a valuable opportunity for biopharma leaders to connect with top oncology physicians, clinicians, influential decision-makers and industry innovators — all in one place.
Accelerate is where meaningful collaborations ignite, breakthrough ideas emerge and transformative solutions take root. By curating a presence at Accelerate, biopharma leaders will be at the forefront of driving progress, expanding their impact and forging lasting partnerships that elevate community cancer care for years to come.
Discover how InspiroGene by 51Âþ»appis collaborating with Biologics by 51Âþ»appto streamline cell and gene therapy delivery and accelerate patient access to treatments.
The efforts and innovations enabling local cancer care practices to provide advanced, personalized therapies close to patients’ homes
Learn how we help accelerate innovative therapy launches so providers can access them when and where patients need them most.
Biopharma and community oncology must unite in a new patient reality.
How 51Âþ»appconnects biopharma, providers and patients to deliver precision oncology at scale through integrated logistics, specialty pharmacy and high‑touch support.
Sarah Cannon Research Institute (SCRI) offers clinical trials in communities close to home, where 85% of patients seek care.
How community oncology clinics are helping break down barriers to care.
How Sarah Cannon Research Institute’s clinical trials changed Mike’s cancer journey.
How Biopharma and community oncology are working together to solve healthcare’s toughest challenges and build a more resilient future for cancer care.